CN1856305B - 用作尾加压素ⅱ拮抗剂的吡啶衍生物 - Google Patents

用作尾加压素ⅱ拮抗剂的吡啶衍生物 Download PDF

Info

Publication number
CN1856305B
CN1856305B CN2004800277254A CN200480027725A CN1856305B CN 1856305 B CN1856305 B CN 1856305B CN 2004800277254 A CN2004800277254 A CN 2004800277254A CN 200480027725 A CN200480027725 A CN 200480027725A CN 1856305 B CN1856305 B CN 1856305B
Authority
CN
China
Prior art keywords
ethyl
pyridin
piperidin
dimethyl
urea groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800277254A
Other languages
English (en)
Chinese (zh)
Other versions
CN1856305A (zh
Inventor
博里斯·马蒂斯
克劳斯·米勒
米夏埃尔·舍茨
托马斯·韦勒
马丁内·克洛泽尔
约尔格·韦尔克
丹尼尔·比尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1856305A publication Critical patent/CN1856305A/zh
Application granted granted Critical
Publication of CN1856305B publication Critical patent/CN1856305B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
CN2004800277254A 2003-09-26 2004-09-21 用作尾加压素ⅱ拮抗剂的吡啶衍生物 Expired - Fee Related CN1856305B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP03/10746 2003-09-26
EP0310746 2003-09-26
PCT/EP2004/010559 WO2005030209A1 (en) 2003-09-26 2004-09-21 Pyridine derivatives and use thereof as urotensin ii antagonists

Publications (2)

Publication Number Publication Date
CN1856305A CN1856305A (zh) 2006-11-01
CN1856305B true CN1856305B (zh) 2010-04-28

Family

ID=34384524

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800277254A Expired - Fee Related CN1856305B (zh) 2003-09-26 2004-09-21 用作尾加压素ⅱ拮抗剂的吡啶衍生物

Country Status (18)

Country Link
US (1) US7750161B2 (enExample)
EP (1) EP1670470B1 (enExample)
JP (1) JP4851328B2 (enExample)
KR (1) KR20070014108A (enExample)
CN (1) CN1856305B (enExample)
AR (1) AR045949A1 (enExample)
AT (1) ATE427748T1 (enExample)
AU (1) AU2004275488A1 (enExample)
BR (1) BRPI0414777A (enExample)
CA (1) CA2540196C (enExample)
DE (1) DE602004020486D1 (enExample)
IL (1) IL174497A0 (enExample)
MX (1) MXPA06003264A (enExample)
NO (1) NO20061395L (enExample)
RU (1) RU2006113948A (enExample)
TW (1) TW200526630A (enExample)
WO (1) WO2005030209A1 (enExample)
ZA (1) ZA200602442B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
DE10358539A1 (de) * 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
AR051213A1 (es) * 2004-10-12 2006-12-27 Actelion Pharmaceuticals Ltd 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
SE0403084D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
WO2006135694A2 (en) * 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Uii-modulating compounds and their use
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
AU2007337659A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
US6159700A (en) 1997-01-27 2000-12-12 Smithkline Beecham Corporation Method of finding agonist and antagonist to human and rat GPR14
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
HK1044282A1 (zh) * 1998-12-18 2002-10-18 Bristol-Myers Squibb Pharma Company 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU6339200A (en) 1999-07-28 2001-02-19 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor
JP2003518059A (ja) 1999-12-21 2003-06-03 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト
US6544992B1 (en) 1999-12-21 2003-04-08 Smithkline Beecham Corporation Urotensin-II receptor antagonists
CA2394603A1 (en) 1999-12-21 2001-06-28 Dashyant Dhanak Urotensin-ii receptor antagonists
EP1262195A4 (en) 2000-03-07 2003-05-21 Takeda Chemical Industries Ltd VASOACTIVE AGENTS
AU2001271357A1 (en) * 2000-06-21 2002-01-02 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2002000606A1 (en) 2000-06-28 2002-01-03 Takeda Chemical Industries, Ltd. Biphenyl compound
AU2001271018A1 (en) 2000-07-04 2002-01-14 Takeda Chemical Industries Ltd. Gpr14 antagonist
EP1351688A4 (en) 2000-12-11 2006-01-04 Smithkline Beecham Corp UROTENSIN-II RECEPTOR ANTAGONISTS
AU2002239506A1 (en) 2000-12-11 2002-06-24 Smith Kline Beecham Corporation Urotensin-ii receptor antagonists
US6818655B2 (en) 2001-01-26 2004-11-16 Smithkline Beecham Corporation Urotensin-II receptor antagonists
JP2004529132A (ja) 2001-03-27 2004-09-24 アクテリオン　ファマシューティカルズ　リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
WO2002078707A1 (en) 2001-03-29 2002-10-10 Smithkline Beecham Corporation Pyrrolidine sulfonamides
WO2002078641A2 (en) 2001-03-29 2002-10-10 Smithkline Beecham Corporation Pyrrolidine sulfonamides
JP2004525156A (ja) 2001-03-29 2004-08-19 スミスクライン・ビーチャム・コーポレイション ピロリジンスルホンアミド
US20040152692A1 (en) 2001-03-29 2004-08-05 Dashyant Dhanak Pyrrolidine sulfonamides
JP2004529170A (ja) 2001-05-07 2004-09-24 スミスクライン・ビーチャム・コーポレイション スルホンアミド
AR033879A1 (es) 2001-05-07 2004-01-07 Smithkline Beecham Corp Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
WO2002090337A1 (en) 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
EP1387679A4 (en) 2001-05-07 2004-08-11 Smithkline Beecham Corp SULPHONAMIDES
WO2002089740A2 (en) 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
US6849635B2 (en) 2001-05-07 2005-02-01 Smithkline Beecham Corporation Sulfonamides
CA2473892C (en) * 2001-12-04 2010-09-21 Actelion Pharmaceuticals Ltd Novel quinoline derivatives
KR20050043967A (ko) * 2002-09-17 2005-05-11 액테리온 파마슈티칼 리미티드 1-피리딘-4-일-요소 유도체
AR041885A1 (es) 2002-11-06 2005-06-01 Smithkline Beecham Corp Compuesto de sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
WO2004043369A2 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
WO2004043917A1 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
AU2003295408A1 (en) 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
WO2004043366A2 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
WO2004073634A2 (en) 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
WO2004099179A1 (en) * 2003-05-07 2004-11-18 Actelion Pharmaceuticals Ltd Piperazine-alkyl-ureido derivatives

Also Published As

Publication number Publication date
DE602004020486D1 (de) 2009-05-20
AR045949A1 (es) 2005-11-16
WO2005030209A1 (en) 2005-04-07
CA2540196A1 (en) 2005-04-07
CN1856305A (zh) 2006-11-01
US20070043081A1 (en) 2007-02-22
TW200526630A (en) 2005-08-16
IL174497A0 (en) 2006-08-01
WO2005030209A8 (en) 2006-05-11
CA2540196C (en) 2012-03-20
ATE427748T1 (de) 2009-04-15
JP2007506692A (ja) 2007-03-22
EP1670470A1 (en) 2006-06-21
RU2006113948A (ru) 2007-11-10
EP1670470B1 (en) 2009-04-08
AU2004275488A1 (en) 2005-04-07
MXPA06003264A (es) 2006-06-08
ZA200602442B (en) 2007-09-26
NO20061395L (no) 2006-06-22
JP4851328B2 (ja) 2012-01-11
KR20070014108A (ko) 2007-01-31
US7750161B2 (en) 2010-07-06
BRPI0414777A (pt) 2006-11-21

Similar Documents

Publication Publication Date Title
JP6995101B2 (ja) 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物
CN109311847B (zh) 作为血浆激肽释放酶抑制剂的吡唑衍生物
AU2013354278B2 (en) Novel pyridine derivatives
CN105814067B (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
CN103827101B (zh) 双环二氢喹啉-2-酮衍生物
AU2002243692B2 (en) Substituted indoles and their use as integrin antagonists
KR100736063B1 (ko) 치환된 피페리딘, 당해 화합물을 함유하는 약제 및 이의제조방법
TWI599562B (zh) 作爲ｔｔｘ－ｓ阻斷劑之醯胺衍生物
CN109803962A (zh) 囊性纤维化跨膜传导调控蛋白的调节剂、药物组合物、治疗方法以及用于制备所述调节剂的方法
TW200924776A (en) Heteroaryl compounds and uses thereof
TW200813047A (en) Substituted prolinamides, the preparation thereof and the use thereof as medicaments
ZA200502009B (en) 1-Pyridiin-4-yl-urea derivatives.
EP2138482A1 (en) Bicyclic heterocyclic compound
US7750161B2 (en) Pyridine derivatives
EP2733144B1 (en) Novel compound having parp inhibitory activity
KR20090050081A (ko) 응고 인자 ＩＸａ 억제제로서 사용하기 위한 이소세린 유도체
EP3190111B1 (en) Pyrazolo[3,4-c]pyridine derivatives
EP3814337B1 (en) Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
JP2007506692A6 (ja) 新規なピリジン誘導体
CA2804824A1 (en) Substituted quinoline-3-carboxamides as kcnq2/3 modulators
AU2021410119A9 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP4350948B2 (ja) オキシトシン調節活性を有するピロリジンエステル誘導体
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN115594623B (zh) 一种吡咯磺酰类衍生物、及其制备方法与应用
RU2562773C2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100428

Termination date: 20150921

EXPY Termination of patent right or utility model